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INTRODUCTION: Numerous experimental efforts have been undertaken to induce the healing of lesions within
articular cartilage by re-establishing competent repair tissue. Adult mesenchymal stem cells have attracted attention
as a source of cells for cartilage tissue engineering. The purpose of this study was to investigate chondrogenesis
employing periosteal mesenchymal cells.
METHODS: Periosteum was harvested from patients who underwent orthopedic surgeries. Mesenchymal stem cells
were characterized through flow cytometry using specific antibodies. The stem cells were divided into four groups.
Two groups were stimulated with transforming growth factor b3 (TGF-b3), of which one group was cultivated in a
monolayer culture and the other was cultured in a micromass culture. The remaining two groups were cultivated in
monolayer or micromass cultures in the absence of TGF-b3. Cell differentiation was verified through quantitative
reverse transcription-polymerase chain reaction (RT-PCR) and using western blot analysis.
RESULT: In the groups cultured without TGF-b3, only the cells maintained in the micromass culture expressed type
II collagen. Both the monolayer and the micromass groups that were stimulated with TGF-b3 expressed type II
collagen, which was observed in both quantitative RT-PCR and western blot analysis. The expression of type II
collagen was significantly greater in the micromass system than in the monolayer system.
CONCLUSION: The results of this study demonstrate that the interactions between the cells in the micromass culture
system can regulate the proliferation and differentiation of periosteal mesenchymal cells during chondrogenesis
and that this effect is enhanced by TGF-b3.
KEYWORDS: Periosteum; Mesenchymal Stem Cells; Chondrogenesis; High-density Culture; Monolayer Culture.
Mara CS, Sartori AR, Duarte ASS, Andrade ALL, Pedro MAC, Coimbra Ibsen B. Periosteum as a source of mesenchymal stem cells: the effects of tgf-b3
on chondrogenesis. Clinics. 2011;66(3):487-492.
Received for publication on October 9, 2010; First review completed on November 9, 2010; Accepted for publication on December 6, 2010
E-mail: cristianesdm@uol.com.br
Tel.: 55 19 35219587
INTRODUCTION
Articularcartilage exhibits low capacity for self-repair after
joint damage. Previous research has shown that damaged
cartilage tissue shows limited potential for repair or
regeneration due to its avascularity and due to the presence
of relatively few chondrocytes that exhibit low mitotic
activity.
1 In the instance of full-thickness articular cartilage
defects that penetrate the cartilage tissue, the repair of
hyaline cartilage is often performed under restrictive condi-
tions that are frequently insufficient for complete repair.
Articular cartilage defects correlate with pain and joint
dysfunction and remain a practical problem, particularly in
younger patients.
Articular cartilage is a connective tissue, which performs
highly specialized functions that are adapted to the local
needs of the site. In native articular cartilage, the
extracellular matrix (ECM) is primarily composed of a
network-like structure of proteoglycans and type II collagen
among other proteins. Chondrocytes are the cellular
component of the cartilage and are responsible for the
production and degradation of the ECM.
2
Mesenchymal stem cells (MSCs) are undifferentiated
pluripotent cells that are capable of differentiating into
many cell types. Adult human MSCs have been derived
from a variety of tissues and have exhibited the potential of
participating in the growth and repair processes. MSCs are
an attractive source of cells for regenerative medicine
because they can be harvested in a minimally invasive
manner, isolated easily, and expanded without difficulty
while preserving their pluripotent capacities including the
capacity for chondrogenesis. Therefore, MSCs may be a
suitable autogenous cell source for the repair of articular
cartilage.
3,4 Also, factors such as TGF play critical roles in
the compaction and shaping of groups of mesenchymal
cells.
5
Various cell-based therapies have been evaluated for the
treatment of defects in the articular cartilage. Autologous
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487chondrocyte implantation (ACI) is a biological method for
the treatment of large, full-thickness chondral defects of the
knee. Briefly, ACI involves the implantation of a suspension
of cultured autologous chondrocytes beneath a tightly
sealed periosteal flap. Periosteal coverage is a popular
technique for repairing cells or cell/scaffold composites in
cartilage defects.
6 This method also implants a large quantity
of progenitor cells, which differentiate into chondrocytes.
7-9
However, a previous study found that the transplantation of
MSCs or chondrocytes without a periosteal patch would be
advantageous because periosteum may be associated with
hypertrophy or ossification.
10 On the other hand, Brittberg
et al.
6 reported that transplantation using autologous chon-
drocytes produced excellent results in patients with patellar
defects. However, this approach was limited by the number
of acquired chondrocytes and their proliferation rate.
Moreover, it has been well characterized that chondrocytes
cultured in a monolayer for a period of more than two
weeks undergo de-differentiation.
11,12
N-cadherin, a cell-dependent adhesion molecule, is
strongly expressed in condensed mesenchyme and has
demonstrated a role in chondrogenesis in murine cell
lines.
13-15 Therefore, we investigated the activity of perios-
teum-progenitor mesenchymal cells (PPMCs) in high-
density micromass cultures. There are currently no
published reports on the use of this technique in human cells.
The successful employment of cell therapy for the
treatment of cartilage injury requires the determination of
the conditions or parameters that are necessary for the
selection of an appropriate cell. In the present study, our
aim was to evaluate the ability of PPMCs to differentiate
into chondrocytes and express collagen type II by compar-
ing high-density micromass cultures with monolayer




The periosteumsamples were harvested fromtheproximal
tibial tissues of four human donors of various ages (ranging
from 40-60 years) who underwent surgical knee replacement
procedures. According to the protocol described by Jansan
et al.,
16 the tissue samples were rinsed twice with phosphate-
buffered saline (PBS) containing an antibiotic-antimycotic
solution (Sigma, USA). The samples were minced into small
slices and treated with 1% collagenase solution (Sigma, St.
Louis, MO, USA) in PBS for digestion at 37˚C for 20 min. The
collagenase solution was drained and the periosteum-
derived cells were collected after washing with PBS. The cell
suspension was centrifuged at 1200 RPM, and the cell pellet
was re-suspended in low-glucose Dulbecco’s modified
Eagle’s medium (DMEM-GibcoH) supplemented with 10%
fetal bovine serum (FBS) and 1% antibiotic-antimycotic
solution at 37˚C for one week in a chamber containing 95%
humidified air and 5% CO2. When the cells reached 80%
confluence, they were trypsinized (5 mg trypsin/ml PBS),
washed in PBS, re-suspended in 20 ml medium, and re-
plated into 75-cm
2 bottles (CellstarH) for expansion. After
three passages, the cells were trypsinized again and analyzed
using flow cytometry (FACsort, BD, San Jose, CA, USA). The
following monoclonal antibodies were used: CD90-PECY5,
CD 105-PE, CD 29-FITC, CD73-PE, STRO-PE, CD34-PE, CD
45-SPRD and HLA DR-FITC. These antibodies were
employed because they are markers of mesenchymal
progenitor cells, which do not express the typical hemato-
poietic antigens.
17
For immunophenotypic characterization, MSCs at the
third passage were trypsinized, harvested, washed once
with PBS, and re-suspended in PBS. Cells (1610
5 per
sample) were stained at room temperature for 30 min with
isotype control mAbs or with specific anti-human anti-
bodies. These samples were mixed gently and incubated for
20 min at 4˚C in the dark, then washed and re-suspended in
staining buffer (PBS-BSA). Data from 10,000 events were
recorded, and flow cytometry was used to measure the
binding of antibodies (CD90 PECYS, HLA DR FITC CD34
PE) relative to that of isotype-matched control antibodies.
The specific fluorescence labeling was analyzed using a
FACSCalibur flow-cytometry instrument (Becton Dickinson,
USA) using the Cell Quest software (BD Bioscience, San
Jose, CA, USA).
Chondrogenic Differentiation
After expansion, the mesenchymal cells were re-suspended
in a chondrogenic culture medium consisting of high-glucose
Dulbecco’s modified Eagle’s medium (Gibco), Invitrogen,
C a l i f o r n i a ,U S A ,1 0n g / m lT G F - b3 (R&D Systems), 100 nM
dexamethasone,16ITS
+1premix,40mg/mlproline,and25mg/
ml ascorbate-2-phosphate (all obtained from Sigma-Aldrich,
Poole, U.K., http://www.sigmaaldrich.com).
18-20 To achieve
chondrogenesis in high-density cell culture, micromass-
culture cells were seeded at a density of 5610
5 cells per
100 mlo fm e d i u mo n t od r yw e l l si na9 6 - w e l lp l a t e( C o r n i n g
LifeH).Aftertwohours,thewellswereslowlyfilledwith0.2ml
of chondrogenic medium in which the cells were maintained
for 21 days at 37˚Ci n5 %C O 2 and 95% air. The medium was
refreshed every three to four days. A second model of culture
(i.e., the monolayer system) was applied by seeding cells into
Costar six-well cell-culture plates (Corning) at a density of
1610
6 cells/cm
2. The medium in this system was also changed
every three to four days.
RNA Isolation, Reverse Transcription and RT-PCR
TotalmRNAwasextractedandpreparedusingtheTRIZOL
reagent according to the manufacturer’s instructions (Invi-
trogenTM Life Technologies, Carlsbad, CA92008, USA). Total
RNA (1 mg) was treated with 1 U of deoxyribonuclease I
(DNase I) (InvitrogenTM Life Technologies, Carlsbad,
CA92008, USA) to digest any contaminating genomic DNA.
Reverse transcription was performed using SuperScriptII
(Invitrogen) according to the manufacturer’s protocol.
Quantitative PCR was conducted using SYBR green (applied
quantitative real-time PCR was performed on a 96-well-plate
ABI Prism 7000 Sequence Detection machine; Applied
Biosystems, Foster City, CA) from the SYBR Green PCR
Master Mix (Applied Biosystems, Foster City, CA). The total
volume (12 ml) of each PCR reaction contained 6 ml SYBR
Green PCR Master Mix, 10 ng cDNA (3 ml), and 150 pM (3 ml)
of each of the forward and reverse primers.The real-time PCR
reaction was carried out at 95˚C for 10 min (activation), 40
cyclesof 95˚C for 15 sec,60˚C for 20 sec, 72˚C for 20 sec (ampli-
fication), and 72˚C for 1 min (final extension). The melting
curves were acquired after the Polymerase Chain Reaction
(PCR) to confirm the specificity of the amplified products. A
standard curve, based on the threshold values of the cycle,
was used to evaluate gene expression. Glyceraldehyde 3
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488phosphate dehydrogenase (GAPDH) was employed as an
internal control.
Primer Sequences
The primer sequences for all genes were designed using
the ABI Primer Express program (Applied Biosystems,
Foster City, CA, USA). The specific primers that were used
are listed in Table 1.
Western Blot Analysis
The proteins secreted by the cells into the culture medium
were analyzed as follows. The proteins were precipitated
using 2 mg/ml of pepsin (Sigma-AldrichH) and 30 ml/ml of
acetic acid, glacial P.A. The samples were maintained in
30˚C for 30 min and then stored overnight at 4˚Co na
shaker. Next, the samples were centrifuged for 90 min at
6400 RPM. Finally, the pellets were washed twice with PBS
buffer, and the quantity of protein was determined using a
spectrophotometer. Next, 30 mg of protein was separated on
a 10% SDS-PAGE (sodium dodecyl sulfate)-polyacrylamide
gel electrophoresis) gel and transferred onto a nitrocellulose
Hybond membrane (Amersham) using trans-blot apparatus
(Invitrogen). The membranes were blocked with 5% (v/v)
skimmed milk in PBS containing 0.1% Tween 20. Finally, the
blot was sequentially incubated with a 1:2000 diluted
polyclonal type II collagen antibody (ChemiconH) capable
of recognizing the C-terminal telopeptides of human type II
collagen, which has a molecular weight of 70 kD (21). The
antibody was rinsed three times with PBS containing 0.1%
Tween 20 and then incubated with a peroxidase-conjugated
secondary antibody against rabbit IgG. The signals were
visualized using an ECL kit (Amersham Biosciences UK
Limited Chalfont Buckinghamshire, England).
Statistical Analysis
Statistical analysis was performed using the one-way
analysis of variance (ANOVA) test with commercially
available software (InStat; GraphPad Software, San Diego,
CA, USA, http://www.graphpad.com). The confidence
interval was 95%. Considering the multiple comparisons
between groups, P values below 0.05 were defined as
significant.
RESULTS
The MSC which firmly attached to the surface of the cell-
culture plate, formed colonies, and presented spindle-
shaped or fibroblast-like morphology and agranular appear-
ance. The sub-cultured cells grew in a monolayer and
attained a stable, fibroblast-like morphology with no signs
of granulation (Figure 1).
The expanded cells exhibited cell-surface antigens that are
typically associated with mesenchymal stem and progenitor
cells. The results of immunophenotypic characterization of
the PPMCs (where the percentage of cells that were positive
for the cell-surface markers was determined using flow
cytometry) indicated that the cells were homogeneously
positive for the following antigens: CD90 PE: 77.29%, CD105
PE: 94.89%, CD29 FITC: 93.33%, CD73: 92.47%, STRO1 PE:
31.41%, CD34 PE: 3.11%, CD45 S PRD: 4.63%, HLA-DRFITC:
0.53% (Figure 2).
RT – PCR
After three weeks, the levels of type II collagen and
aggrecan mRNA were significantly higher upon chondro-
genic induction compared to the control group (i.e.,
monolayer culture without TGF-b3) (P,0.001). The expres-
sion of both genes, type II collagen and aggrecan, was
highest in the cells that were cultured in the micromass
system in the presence of TGF-b3( P,0.001). The cells that
were cultured in the micromass system without TGF-b3
were not statistically different from the cells that were
cultured in the monolayer system with TGF-b3( P.0.05).
The cells that were cultured in the monolayer system
without TGF-b3 exhibited no expression of type II collagen
(Figure 3).
Western Blot
The expression of type II collagen in cultured cells was
also greater in the cells that were cultured with TGF-b3
compared to the cells that were cultured without TGF-b3.
Micromass cultures that were cultivated without TGF-b3
also exhibited higher type II collagen expression compared
to the monolayer cultures cultivated with TGF-b3, corrobor-
ating the real-time PCR results. The cells that were cultured
in a monolayer without TGF-b3 did not express type II
collagen (Figure 3).
DISCUSSION
Articular cartilage shows limited capacity for self-repair
after joint damage. The regeneration of articular cartilage
using cell-based therapies requires the identification of
available cells that have the ability to differentiate into
chondrogenic cells. Several clinical studies have investi-
gated methods such as abrasion arthroplasty,
22 microfrac-
Table 1 - The primer sequences used in qRT-PCR. Primer
sequences for all genes were designed using the ABI
Primer Express program (Applied Biosystems, Foster City,
CA, USA).
Collagen II Forward GGCAATAGCAGGTTCACGTACA





Figure 1 - The morphology of PPMCs. The cells exhibited a
fibroblastoid morphology in a monolayer and then attained a
stable, fibroblast-like morphology with no signs of granulation.
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489Figure 2 - The expanded cells exhibited cell-surface antigens that are typical of mesenchymal stem and progenitor cells. The results of
the immunophenotypic characterization of the PPMCs indicated that the cells were homogeneously positive for the following
antigens: CD90 PE: 77.29%, CD105 PE: 94.89%, CD29 FITC: 93.33%, CD73: 92.47%, STRO1 PE: 31.41%, CD34 PE: 3.11%, CD45 S PRD:
4.63% and HLADR – FITC: 0.53%.
Figure 3A - The expression of type II collagen. RT-PCR analysis was conducted after three weeks of culturing of the periosteum-derived
cells in monolayer and micromass systems. We observed that in the micromass culture, the addition of TGF-b3 (P mo TGF and P mi TGF)
increased the expression of type II collagen (P,0.001). No statistical difference was observed between cells grown in a monolayer in the
presence of TGFb3 (P mo TGF) and cells grown in a micromass without TGF-b3 (P mi no TGF) (P.0.05). B. The expression of aggrecan. RT-
PCR analysis was conducted after three weeks of culturing of the periosteum-derived cells in both monolayer and micromass systems.
We observed that in the micromass culture, the cells grown in the presence of TGFP-b3 exhibited increased expression of Aggrecan
(P,0.001) compared to the cells grown in the monolayer with TGF-b3 (P mi TGF and P mo TGF). The cells in the micromass culture
without TGF-b3 (P mi no TGF) expressed less aggrecan compared to the cells in the monolayer culture with TGF-b3 (P mo TGF), (P,0.01).
Chondrogenesis from periosteum





transplantation of autologous chondrocytes into the defects.
Currently, the autologous chondrocyte implant (ACI)
6 is the
most widely employed surgical procedure for effecting the
regeneration of articular cartilage. However, this procedure
remains somewhat risky because chondrocytes in suspen-
sion can leak from the graft site after load-bearing activity is
resumed. Moreover, long-term studies have reported that
grafts can produce fibrocartilage.
31 The origins of the cells
employed by this technique remain unclear (i.e., we do not
know whether the cells originate from the patient’s
chondrocytes or from the periosteal tissue) because studies
have shown that periosteum contains cells that are capable
of differentiating into chondrocytes.
32,33 In this study, we
induced chondrogenesis by culturing MSCs derived from
periosteum in a micromass system in the presence of TGF-
b3. We optimized culture conditions for chondrogenesis
through high-density micromass plating and TGF-b3 treat-
ment. A previous study concluded that the use of
periosteum coverage for retaining chondrocytes within an
osteochondral defect exhibited no advantage compared to a
type I/III collagen membrane. However, such studies
demonstrated no statistical difference in the outcome with
regard to arthroscopic findings of both clinical and func-
tional assessment after one year.
32 Sub-periosteal injection
of TGF-b3 has been known to stimulate the proliferation of
periosteal mesenchymal cells to induce chondrogenic
differentiation
34-36 as well as mediate differentiation into
other mesenchymal cell types.
37 Thus, the aim of our study
was to determine the effect of TGF-b3 on PPMCs in high-
density micromass cultures compared to those in monolayer
systems. Previous studies have demonstrated the capacity
of PPMCs to cause chondrogenesis.
16 In our study, we also
found that type II collagen mRNA was expressed more
robustly in a micromass culture system than in a monolayer
system following treatment with TGF-b3. Moreover, we also
found that cells kept in a micromass culture system produce
type II collagen even in the absence of TGFP-b3. We
attributed this finding to the activity of adhesion molecules,
which play a pivotal role in chondrogenesis. As other
researchers have demonstrated,
38 these molecules are
upregulated when the cells are grown in micromass
cultures. Specifically, in high-density micromass cultures,
these cells express the adhesion molecule N-cadherin,
which plays an important role in the regulation of the
chondrocytic phenotype.
14,15,39 Cellular condensation is a
required early step in the initiation of mesenchymal
chondrogenesis because this condensation is accompanied
by the elevated expression of N-cadherin in vitro. High cell
density has also been reported as a requirement for
mesenchymal chondrogenesis.
40 Our results suggest that
the in vitro pretreatment of micromass cultures with TGF-b3
increases the ability of periosteum to undergo chondrogen-
esis and produce hyaline cartilage. Our findings also
suggest that periosteum can be used as a source of
chondrocytes for autologous implants because the perios-
teum cover provides cells for the repair of the lesion.
Moreover, periosteum-derived chondrocytes can be used
for the generation of new transplants by being applied to a
different scaffold. Further studies using periosteal chon-
drocytes grown in micromass cultures are required to
evaluate whether the chondrocytes maintain their pheno-
types in animal models of chondral defects.
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